GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care
Biomolecules · 11.06.2026 · 16 (6) · 857
DOI: 10.3390/biom16060857 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 11.06.2026. Verfasst von Irina-Georgeta Sufaru und 10 weiteren Autor:innen. Beteiligte Einrichtung: Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Periodontal Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes and obesity and are increasingly relevant in periodontal and implant practice. This review covers mechanisms, preclinical and early human evidence, and practical periodontal considerations; the structured database search is conducted in accordance with the Scale for the Assessment of Narrative Review Articles (SANRA) and the International Committee of Medical Journal Editors (ICMJE) principles. Two pathways explain GLP-1RAs’ relevance: indirect effects from better glycemic control, weight loss, and reduced inflammation; and direct tissue effects involving GLP-1R signaling and the GLP-1/dipeptidyl peptidase-4 (DPP-4) axis. Preclinical studies show reduced inflammation, osteoclast activity, and alveolar bone loss, along with improved periodontal stem cell function under hyperglycemia or inflammation via Nuclear Factor-kappaB (NF-kappaB), Wingless-related integration site (Wnt)/beta-catenin, and Mitogen-Activated Protein Kinase (MAPK) pathways. Animal studies on implants and local delivery, including exendin-4 platforms, suggest osteometabolic benefits. Human data are limited and mostly observational, and confounders include metabolic status, smoking, medication, and nutrition. Oral side effects such as xerostomia and dehydration are also noted. At present, GLP-1RA therapy should be regarded as a contextual modifier of periodontal risk and healing capacity rather than as a stand-alone periodontal therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
- Department of Periodontology, Faculty of Dental Medicine, Anton Sculean Research Center for Periodontal and Peri-Implant Diseases, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
ORCID-Profile: Irina-Georgeta Sufaru, Stefan-Ioan Stratul, Gianina Iovan, Diana Hanu, Sorina Mihaela Solomon
Zitieren
APA
Sufaru, I. G., Vasiliu, B. C., Hancianu, M., Stratul, S. I., Tatarciuc, M. S., Iovan, G., Tatarciuc, D., Rudnic, I., Hanu, D., Paduraru, S., & Solomon, S. M. (2026). GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care. Biomolecules, 16(6), 857. https://doi.org/10.3390/biom16060857
Vancouver
Sufaru IG, Vasiliu BC, Hancianu M, Stratul SI, Tatarciuc MS, Iovan G, et al. GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care. Biomolecules. 2026;16(6):857. doi:10.3390/biom16060857
BibTeX
@article{Sufaru2026,
author = {Sufaru, Irina-Georgeta and Vasiliu, Bogdan Constantin and Hancianu, Monica and Stratul, Stefan-Ioan and Tatarciuc, Monica Silvia and Iovan, Gianina and Tatarciuc, Diana and Rudnic, Ioana and Hanu, Diana and Paduraru, Sorina and Solomon, Sorina Mihaela},
title = {GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {6},
pages = {857},
doi = {10.3390/biom16060857}
}
EUVIMED